Artículos relacionados
Área salud
Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience From 2 Tertiary Referral Centers
mayo 16, 2025
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 116. Núm. 3. (marzo 2025)
Introduction Clinical trials have validated the use of nivolumab and pembrolizumab as adjuvant therapies regarding relapse-free survival in patients with resected stage III and IV melanoma. Evidence in real-world patients is currently limited. Material and […]
Área salud
[Translated article] Update on the Diagnosis and Management of Desmoplastic Melanoma
diciembre 27, 2022
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 113. Núm. 1. (Enero 2022)
Desmoplastic melanoma (DM) accounts for 0.4% to 4% of all melanomas. These skin tumors are mainly formed by amelanotic spindled melanocytes immersed in an abundant collagen stroma and are classified as pure when the desmoplastic […]
Área salud
Avelumab to treat Merkel cell carcinoma: real-life experience in a dedicated oncology center
enero 15, 2025
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 116. Núm. 1. (enero 2025)
The arrival of immunotherapy has revolutioned the management of patients with metastatic Merkel cell carcinoma (MCC). We conducted an observational, retrospective study of 14 cases treated with avelumab. The response rate was 57%: complete response […]
